Pemetrexed for the first-line treatment of non-small-cell lung cancer

  • Technology appraisal guidance
  • TA181
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group, The University of Liverpool:

  • Fleeman N, Bagust A, McLeod C, et al. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), February 2009

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Lilly UK (pemetrexed)

II) Professional/specialist and patient/carer groups:

  • British Thoracic Oncology Group

  • British Thoracic Society (Lung Cancer and Mesothelioma Working party)

  • General Practice Airways Group

  • Macmillan Cancer Support

  • Marie Curie Cancer Care

  • Roy Castle Lung Cancer Foundation

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians' Intercollegiate Lung Cancer Group

  • Royal College of Radiologists

III) Other consultees:

  • Department of Health

  • Southampton City PCT

  • Welsh Assembly Government

  • West Sussex PCT

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Liverpool Reviews and Implementation Group, The University of Liverpool

  • National Collaborating Centre for Cancer

  • National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)

  • NHS Quality Improvement Scotland

  • Sanofi Aventis

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on pemetrexed for NSCLC by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Ms Catherine Docherty, Lung Cancer Clinical Nurse Specialist, nominated by Royal College of Nursing – clinical specialist

  • Professor David Ferry, Consultant Medical Oncologist, nominated by Royal College of Physicians – clinical specialist

  • Dr Jesme Fox, nominated by Roy Castle Lung Cancer Foundation – patient expert